1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CCR
  4. CCR Inhibitors

CCR Inhibitors

CCR1

CCR2

CCR3

CCR4

CCR5

CCR6

CCR7

CCR8

CCR9

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

CCR Inhibitors, Agonists, Antagonists & Chemicals
Product Name CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 Purity
Maraviroc        
MIP-1α-CCR5, IC50: 3.3 nM (in HEK-293 cell membrane)
MIP-1β-CCR5, IC50: 7.2 nM (in HEK-293 cell membrane)
RANTES-CCR5, IC50: 5.2 nM (in HEK-293 cell membrane)
        99.71%
RS 504393  
CCR2, IC50: 89 nM
              99.43%
INCB3344  
hCCR2, IC50: 5.1 nM
mCCR2, IC50: 9.5 nM
              99.73%
Ilacirnon  
hCCR2, Kd: 2.3 nM (in monocytes)
CCR2, IC50: 3 nM (in THP-1 cells)
   
CCR5, IC50: 7 μM (in Activated T lymphocytes)
        99.87%
BX471
MIP-1α-CCR1, Ki: 1 nM
RANTES-CCR1, Ki: 2.8 nM
MCP-3-CCR1, Ki: 5.5 nM
                99.94%
RS102895 hydrochloride
CCR1, IC50: 17800 nM
CCR2, IC50: 360 nM
              99.87%
Cenicriviroc  
CCR2, IC50: 5.9 nM
   
CCR5, IC50: 0.29 nM
        99.01%
TAK-779  
MCP-1-CCR2b, IC50: 27 nM (in CHO/CCR5 cells)
   
MIP-1α-CCR5, IC50: 1 nM (in CHO/CCR5 cells)
MIP-1β-CCR5, IC50: 1 nM (in CHO/CCR5 cells)
RANTES-CCR5, IC50: 1.4 nM (in CHO/CCR5 cells)
        99.73%
PF-4136309  
Human CCR2, IC50: 5.2 nM
Mouse CCR2, IC50: 13 nM
Rat CCR2, IC50: 17 nM
              99.59%
Zelnecirnon      
CCR4
          99.84%
CCR6 inhibitor 1          
Moneky CCR6, IC50: 0.45 nM
Human CCR6, IC50: 6 nM
Human CCR7, IC50: 9400 nM
    99.87%
CCR6 antagonist 1          
CCR6
      99.55%
AZ084              
CCR8, Ki: 0.9 nM
  99.69%
AZD2098      
CCR4
          99.84%
ZK756326 dihydrochloride              
CCR8, IC50: 1.8 μM (in U87 cells)
  99.88%
BX471 hydrochloride
MIP-1α-CCR1, Ki: 1 nM
RANTES-CCR1, Ki: 2.8 nM
MCP-3-CCR1, Ki: 5.5 nM
                99.51%
R243              
CCR8
  98.01%
CCR2 antagonist 4 hydrochloride  
CCR2b, IC50: 180 nM
              99.86%
GW 766994    
CCR3, pKi: 7.86
            99.73%
C-021      
CCR4
          99.94%
CCR7 Ligand 1            
Human CCR7, Kd: 3 nM
    99.62%
J-113863
CCR1, IC50: 0.9 nM (Human CCR1)
CCR1, IC50: 5.8 nM (Mouse CCR1)
 
CCR3, IC50: 0.58 nM (Human CCR3)
CCR3, IC50: 460 nM (Mouse CCR3)
            ≥99.0%
BMS-813160  
CCR2, IC50: 6.2 nM
   
CCR5, IC50: 3.6 nM
        99.93%
Vercirnon                
CCR9, IC50: 10 nM
98.26%
Cenicriviroc Mesylate  
CCR2, IC50: 5.9 nM
   
CCR5, IC50: 0.29 nM
        99.04%
K777      
CCR4
          99.77%
INCB 3284  
MCP-1-hCCR2, IC50: 3.7 nM
              99.30%
DAPTA        
gp120BaL/sCD4-CCR5, IC50: 55 pM (in Cf2Th/synR5 cells)
gp120CMCM235/sCD4-CCR5, IC50: 0.32 nM (in Cf2Th/synR5 cells)
        99.85%
SB-328437    
CCR3, IC50: 4.5 nM
            98.48%
ALK4290    
CCR3, Ki: 3.2 nM
            99.21%
BMS CCR2 22  
CCR2, IC50: 5.1 nM
              99.87%
LMD-009              
CCR8, EC50: 11-87 nM
  99.76%
CCR2 antagonist 1  
CCR2, Ki: 2.4 nM
              98.00%
RS102895
CCR1, IC50: 17800 nM
CCR2, IC50: 360 nM
              99.97%
CCR2-RA-[R]  
CCR2, IC50: 103 nM (in U2OS-CCR2 cells)
              99.71%
PF-07054894          
CCR6
      99.12%
BI 639667
CCR1, IC50: 1.8 nM (in Ca2+ flux assay)
                99.47%
Vicriviroc maleate        
CCR5, Ki: 2.5 nM
        99.91%
YM022
CCR1, Ki: 63 nM
CCR2, Ki: 68 pM
              99.93%
CCR1 antagonist 9
CCR1, IC50: 6.8 nM (in calcium flux assay)
                99.93%
Mogamulizumab      
CCR4
         
CCR8 antagonist 1              
CCR8, Ki: 1.6 nM
  98.71%
AZD2423  
CCR2
              99.46%
Plozalizumab  
CCR2
             
AZD-5672        
CCR5, IC50: 0.32 nM
       
CCR4-351      
CCR4
          98.02%
CKLF1-C19    
CCR3
CCL17-CCR4
          99.95%
Aplaviroc hydrochloride        
CCR5
        99.76%
CCR8 antagonist 2              
CCR8
  99.71%
C-021 dihydrochloride      
CCR4
          99.92%
Vercirnon sodium                
CCR9, IC50: 10 nM
99.13%
CCR4 antagonist 4      
CCR4, IC50: 0.02 μM
          99.72%
Nifeviroc        
CCR5
        98.17%
CCR2 antagonist 4  
CCR2b, IC50: 180 nM
              99.89%
CCR4 antagonist 3      
[125I]-TARC-CCR4, IC50: 1.7 μM
          99.94%
CCX354
CCR1
                99.18%
CCR4-351 hydrochloride      
CCR4
          98.59%
PF-04634817  
Rat CCR2, IC50: 20.8 nM
   
CCR5, IC50: 470 nM
        98.87%
INCB3344 R-isomer  
CCR2
             
BMS-817399
CCR1, IC50: 1 nM
                99.83%
JNJ-41443532  
hCCR2, IC50: 37 nM
mCCR2, Ki: 9.6 μM
              98.79%
Aplaviroc        
CCR5
       
MK-0812  
CCR2
              99.75%
CCR3 antagonist 1    
CCR3
            98.95%
INCB 3284 dimesylate  
MCP-1-hCCR2, IC50: 3.7 nM
              ≥98.0%
PF-04634817 succinate  
Rat CCR2, IC50: 20.8 nM
   
CCR5, IC50: 470 nM
        ≥99.0%
CCR5 antagonist 3        
CCR5, IC50: 15.90 nM
       
CCR1 antagonist 10
CCR1
               
Fuscin        
CCR5
       
Cosalane            
Human CCR7
Murine CCR7
   
Cosalane            
Human CCR7
Murine CCR7
   
SB-649701              
CCR8, pIC50: 7.7
 
CCR5 antagonist 2        
CCR5, IC50: 8.34 nM
       
CCR5 antagonist 1        
CCR5
       
JNJ-27141491  
hCCR2
             
CKLF1-C27 TFA      
CCR4
         
Maceneolignan H    
CCR3
           
BMS-639623    
CCR3, IC50: 0.3 nM
           
CKLF1-C27      
CCR4
          98.50%
CCR8 antagonist 3              
CCR8, IC50: 0.062 μM